AIONOS is signalling a dramatic shift in how enterprises build and deploy AI, with CTO Arjun Nagulapally asserting that the industry is on the brink of a seismic leap rather than a gradual shift. “I would not even say transformation, it’s going to be a revolution,” he said in an exclusive conversation with AIM. At the centre of this shift is the company’s strategy to treat AI as foundational infrastructure. Describing AI as “the new programming language,” Nagulapally explained that AIONOS now develops all its products using multimodal capabilities—spanning voice, text and vision—across domains such as healthcare, logistics, travel and telecommunications.
Healthcare, in particular, is already witnessing tangible outcomes from this approach. Nagulapally pointed out that radiology workflows and patient engagement systems are benefiting from faster, AI-driven interpretation and communication. Yet he also emphasised the inherent risks in deploying these systems at scale. He recalled incidents where AI models misread details from photographs uploaded by patients, cautioning that such inaccuracies could directly influence medical decisions or prescriptions. Highlighting the gravity of these risks, he underscored the need for “guardrails, judgement and traceability” to ensure that the technology augments, rather than endangers, patient care.
To strengthen safety and accountability, AIONOS has built IntelliMate—a decision-logging platform designed to record every action or recommendation made by an AI agent. The system also initiates human intervention during high-stakes or ambiguous scenarios, providing a structured oversight layer. This framework supports the company’s work across a range of leading AI models, including Llama, Mistral, OpenAI systems and Google’s Gemini family. One of the immediate applications has been helping diagnostic labs generate clear, accessible explanations of blood reports, enabling patients to better understand their own health data.
Looking ahead, Nagulapally is optimistic about the trajectory of AI-led innovation in healthcare and beyond. He predicts that the next few years will bring “much more personalised healthcare, new drugs invented, better access and better quality of life.” For AIONOS, this future will be shaped by a combination of advanced multimodal models, responsible deployment frameworks and a commitment to ensuring that AI’s growing capabilities translate into real-world, human-centred impact.
